CACNA1G: IHC Expression in Cancer and Radioligand Target Profile
CACNA1G, calcium voltage-gated channel subunit alpha1 G, is a cell-surface protein. In Human Protein Atlas immunohistochemistry, CACNA1G staining is highest in head and neck cancer (100% of samples positive), thyroid cancer (100% of samples positive) and colorectal cancer (91% of samples positive). Clinical status: FDA-approved drug (any modality).
Is CACNA1G the right target for your program? Rank it against 15,000 targets on dosimetry, internalization and clinical risk.
Analyze CACNA1G freeIs CACNA1G a good radioligand therapy target?
Scored against the six criteria that decide whether a protein can become a radioligand therapy:
- ✅ Cell-surface accessibility: Localized to the cell surface, so a radioligand can reach it from circulation.
- ✅ Tumor expression: High IHC staining in head and neck cancer, 100% of samples positive.
- ❔ Internalization: Not yet assessed.
- ✅ Clinical precedent: FDA-approved drug (any modality)
- ❔ Shedding: Not yet assessed.
- ❔ Normal-tissue dosimetry: Check kidney, liver, bone marrow and salivary expression in the Human Protein Atlas tissue atlas.
CACNA1G IHC staining by cancer type
Protein expression of CACNA1G across 20 cancer types from Human Protein Atlas immunohistochemistry. The score is a weighted staining intensity from 0 to 1; "% positive" is the share of patient samples with detectable staining.
| Cancer type | IHC score | Level | % positive |
|---|---|---|---|
| Head and Neck Cancer | 0.83 | High | 100% |
| Thyroid Cancer | 0.58 | High | 100% |
| Colorectal Cancer | 0.48 | Medium | 91% |
| Pancreatic Cancer | 0.47 | Medium | 100% |
| Breast Cancer | 0.42 | Medium | 83% |
| Skin Cancer | 0.42 | Medium | 75% |
| Neuroendocrine Tumors | 0.42 | Medium | 50% |
| Glioma | 0.39 | Medium | 82% |
| Gastric Cancer | 0.39 | Medium | 83% |
| Liver Cancer | 0.39 | Medium | 83% |
| Prostate Cancer | 0.39 | Medium | 75% |
| Endometrial Cancer | 0.36 | Medium | 82% |
| Bladder Cancer | 0.31 | Medium | 92% |
| Cervical Cancer | 0.31 | Medium | 75% |
| Lung Cancer | 0.31 | Medium | 50% |
| Ovarian Cancer | 0.24 | Medium | 55% |
| Testicular Cancer | 0.22 | Medium | 50% |
| Melanoma | 0.22 | Medium | 33% |
| Lymphoma | 0.17 | Low | 42% |
| Kidney Cancer | 0.06 | Low | 8% |
Is CACNA1G internalized?
Nuclens has not yet extracted internalization evidence for CACNA1G. Internalization matters for radioligands because an internalizing receptor traps the radionuclide inside the tumor cell. Run a free analysis to pull the latest literature.
CACNA1G clinical trials
FDA-approved drug (any modality). Nuclens hasn't indexed trials for CACNA1G yet. Search ClinicalTrials.gov for CACNA1G trials.
CACNA1G normal tissue expression
Normal-tissue expression in dose-limiting organs (kidney, liver, bone marrow, salivary glands) drives radioligand dosimetry risk. Nuclens is re-validating its normal-tissue values, so they are not shown here yet. See CACNA1G in the Human Protein Atlas tissue atlas, and read how normal-tissue expression predicts radioligand dosimetry risk.
CACNA1G gene essentiality (DepMap)
CRISPR knockout effect across 1257 cancer cell lines: -0.21 (not essential). Radioligands kill by radiation, not by blocking the target, so essentiality matters less than for inhibitors. A non-essential target can still be an excellent radioligand target.
Related head and neck cancer radioligand targets
EGFR · c-MET (MET) · HER3 (ERBB3) · ITGAV · SSTR2 · B7-H3 (CD276) · STEAP2 · HER2 (ERBB2)
See all radioligand therapy targets in head and neck cancer.
See how CACNA1G ranks against 15,000 targets for your indication.
Analyze CACNA1G freeData sources
Subcellular localization: UniProt via Open Targets (CC BY 4.0 / CC0). Tumor immunohistochemistry: Human Protein Atlas (CC BY-SA 4.0). Clinical trials: ClinicalTrials.gov (public domain). Gene essentiality: DepMap (CC BY 4.0). Internalization and shedding: AI-extracted from PubMed abstracts, so verify against the cited papers before relying on them. Nuclens is a first-pass triage layer, not a substitute for wet-lab validation or clinical dosimetry. Derived expression data on this page is shared under CC BY-SA 4.0.